

#168 Diabetes Update with Jeff Colburn MD
Aug 26, 2019
Join Jeff Colburn, an expert in endocrinology and co-author of the VA Diabetes Guidelines, as he dives into the latest in diabetes management. He discusses the challenges of A1C testing and controversies around targets while highlighting innovative treatments like SGLT2 inhibitors and GLP-1 agonists. Colburn emphasizes the importance of lifestyle interventions and shares insights on transitioning patients to insulin therapy. Discover the balance between effective management and patient education in navigating complex diabetes care.
AI Snips
Chapters
Books
Transcript
Episode notes
Understanding A1C Test Limitations
- A1C has variability and can be affected by health conditions, making exact targets challenging.
- Targets should be individualized considering hypoglycemia risk and patient context.
Tailor A1C Targets to Patients
- Use A1C target ranges based on patient lifespan and microvascular disease burden.
- Avoid strict one-size-fits-all targets to reduce hypoglycemia and harm.
Glycemic Control vs. Macrovascular Disease
- Tight glucose control mainly prevents microvascular complications, less so macrovascular ones.
- Hypertension and lipid control play bigger roles in macrovascular disease prevention.